Omega-3-acid ethyl esters
- Generic Name
- Omega-3-acid ethyl esters
- Brand Names
- Lovaza, Omtryg
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 308081-97-2
- Unique Ingredient Identifier
- D87YGH4Z0Q
- Background
Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other...
- Indication
Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG).
- Associated Conditions
- Severe Hypertriglyceridemia (sHTG)
- Associated Therapies
- -
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase 1
Withdrawn
- Conditions
- Interventions
- Biological: avelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab paclitaxelBiological: nivolumabDrug: LovazaDrug: OxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-fluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: omega-3-acid ethyl estersRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-051Biological: ETBX-061Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167164
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-fluorouracilDrug: LeucovorinDrug: nab-paclitaxelBiological: NivolumabDrug: omega-3-acid ethyl estersRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167177
Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15330
- Registration Number
- NCT02285166
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2016-06-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT02189252
- Locations
- 🇨🇦
Research Site, Chocoutimi, Quebec, Canada
Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3084
- Registration Number
- NCT02153073
Fish Oils and Adipose Inflammation Reduction
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 29
- Registration Number
- NCT02010359
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue
Early Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Milton S. Hershey Medical Center
- Registration Number
- NCT01784042
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT01431690
Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 100
- Registration Number
- NCT01048502
- Locations
- 🇺🇸
Clinical and Translational Research Center (CTRC); Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath